|
The cyclothiazomycins are a group of natural products produced by various ''Streptomyces'' species of bacteria. These compounds are ribosomally synthesized and post-translationally modified peptides (RiPPs) and can be further classified as thiopeptides. The overall structure of the cyclothiazomycins comprises a macrocyclic bicyclic peptide containing several thiazoles and thiazolines. The cyclothiazomycins are reported to have multiple inhibitory effects ranging from decreasing blood pressure to interfering with RNA transcription; they also exhibit some antibiotic activity. == History == Cylothiazomycin A was first isolated from ''Streptomyces'' sp. NR0516 in 1991. The structure of cyclothiazomycin A was solved via NMR spectroscopy and chemical degradation. Previously, a peptide compound 5102-II had been isolated in 1982 from ''Streptomyces hygroscopicus'' 10-22. The discovery of the genes responsible for the biosynthesis of cyclothiazomycin in 2010 showed that 5102-II and cyclothiazomycin A were the same compound. Structural analogues cyclothiazomycin B1 and B2 were isolated from ''Streptomyces'' sp. A307 and solved in 2006 with the help of high-resolution mass spectrometry and NMR spectroscopy. A third analogue, cyclothiazomycin C, was discovered in 2014 with the aid of genome mining, nucleophilic 1,4-addition labeling reactions, high resolution mass spectrometry, and NMR spectroscopy. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cyclothiazomycin」の詳細全文を読む スポンサード リンク
|